Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus

Core Insights - Hyundai Bioscience has announced a significant advancement in its antiviral strategy with the introduction of Xafty, a broad-spectrum antiviral drug, aimed at addressing multiple viral infections simultaneously [1][2][4] Company Strategy - The company has unveiled a "One Drug, Two Tracks" strategy, targeting Dengue in Vietnam and respiratory viruses (Flu, COVID, RSV) in the U.S. using the same drug [1][4] - The clinical strategy was developed in collaboration with Dr. Davey Smith, a prominent figure in the field of medicine [2][4] Clinical Development - Hyundai Bioscience is entering Phase 2 clinical trials in the U.S. for Xafty, which is based on niclosamide and modified for enhanced bioavailability [1][6] - The company is prepared to submit its Investigational New Drug (IND) application to the FDA immediately [5] Market Context - Dr. Smith has identified the current U.S. healthcare crisis as a "tripledemic" involving Influenza, RSV, and COVID-19 variants, highlighting the need for a unified treatment approach [3][4] - The "Basket Trial" design of Xafty is presented as an efficient solution to combat the multi-viral crisis [4] Vision for the Future - The company envisions 2026 as a pivotal year for public health, aiming to shift from reactive to pre-emptive measures against viral infections [5]